Brief: US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis Bullosa
29/04/2025 11:13
April 29 (Reuters) - Abeona Therapeutics Inc ABEO.O: U.S. FDA APPROVES ZEVASKYN™ (PRADEMAGENE ZAMIKERACEL), THE FIRST AND ONLY CELL-BASED GENE THERAPY FOR PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB) ABEONA THERAPEUTICS INC - ZEVASKYN TO BE AVAILABLE THROUGH QUALIFIED TREATMENT CENTERS IN 3Q 2025 Source text: ID:nGNXbzwPMP Further company coverage: ABEO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abeona Therapeutics
See all newsBrief: Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ultragenyx rises after FDA nod for rare disorder drug
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce
U.S. STOCKS ON THE MOVE-Cerebras, Madison Square Garden Sports